GLP-1 drugs provide cardiovascular protection
A new meta-analysis of relevant clinical studies suggests that GLP 1 weight-loss drugs provide protection against heart attacks, strokes and premature death for up to 2.7 years. The […]
A new meta-analysis of relevant clinical studies suggests that GLP 1 weight-loss drugs provide protection against heart attacks, strokes and premature death for up to 2.7 years. The […]
A healthy diet, weight loss, and increased physical activity can effectively prevent type 2 diabetes. However, not all individuals at elevated diabetes risk benefit equally from lifestyle interventions. […]
People with type 1 diabetes who took GLP-1 receptor agonist (GLP-1-RA) drugs for weight loss or better blood-sugar control had significantly reduced risks of major cardiovascular events and […]
A new analysis led by researchers at the Johns Hopkins Bloomberg School of Public Health finds that out-of-pockets caps on insulin for Medicare Part D beneficiaries have reined […]
A one-size-fits-all approach to prediabetes treatment may miss the opportunity to implement an early, more intensive, tailored prevention approach for those with the highest risk of developing Type […]
To be healthy, conventional wisdom tells us to exercise and limit fatty foods. Exercise helps us lose weight and build muscle. It makes our hearts stronger and boosts […]
A large McGill University study has found that two classes of medications commonly prescribed for Type 2 diabetes, both incretin-based, are associated with a reduced risk of dementia. […]
Diabetes mellitus is a chronic metabolic disorder and one of the most prevalent non-communicable diseases worldwide. On average, one in ten adults is affected. The number of people […]
A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) inhibitors—such as empagliflozin (Jardiance) and dapagliflozin (Farxiga)—or glucagon-like peptide-1 (GLP-1) […]
Orforglipron , an investigative and oral GLP-1 drug, appears to enable adults with obesity and Type 2 diabetes to achieve significantly more weight loss and improvement in blood […]
A widely prescribed diabetes drug may be sabotaging one of the most trusted strategies for preventing the disease: exercise. That is the conclusion of a Rutgers-led study published in The Journal […]
A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that […]
ADVERTISMENT
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.